The Institute for Clinical and Economic Review’s proposed update to its drug value review framework reiterates support for using real-world evidence in its prescription drug assessments when it is available and reliable.
The proposed update was released on 21 August and will be discussed by ICER during a 4 September webinar....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?